$LNTH Cashflow Statement | Understand Stock

$LNTH

$100.15 +$0.23 (0.23%) Close

$LNTH Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net income
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation, amortization and accretion
Impairment of long-lived assets
Asset retirement obligation acceleration
Gain on interest rate swap termination
Adjustment to the fair value of asset retirement obligation
Amortization of debt-related costs
Changes in fair value of contingent assets and liabilities
Change in fair value of contingent assets and liabilities
Inventory adjustments
Stock-based compensation
Gain on disposal of assets
Gain on sale of RELISTOR licensed intangible asset
Unrealized loss on investment in equity securities
Charges incurred pursuant to acquired in-process research and development
Loss on extinguishment of debt
Deferred taxes
Long-term indemnification receivable
Long-term income tax payable and other long-term liabilities
Other, net
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable
Inventory
Other long-term assets
Other current and noncurrent assets
Accounts payable
Accrued expenses and other current and long-term liabilities
Net cash provided by operating activities
Cash flows from investing activities:
Capital expenditures
Acquisition of in-process research and development
Proceeds from sale of assets
Lending on bridge loan
Cash acquired in acquisition of business
Acquisition of assets, net
Acquisition, net of cash acquired
Evergreen Theragnostics
Life Molecular Imaging Ltd
Purchases of investment in equity securities
Acquisition of exclusive license option
Net cash (used in) provided by investing activities

Cash flows from financing activities:
Equity issuance costs
Debt issuance costs
Proceeds from issuance of long-term debt, net
Payments of long-term debt and other borrowings
Deferred financing costs
Proceeds from interest rate swap termination
Proceeds from stock option exercises
Contingent value rights settlement
Proceeds from employee stock purchase plan
Payments for minimum statutory tax withholding related to net share settlement of equity awards
Repurchase of common stock
Net cash used in financing activities

Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental disclosure of cash flow information
Interest
Income taxes , net of refunds of $28, $2,688 and $25, respectively
Schedule of non-cash investing and financing activities
Additions of property, plant and equipment included in liabilities
Consideration transferred in acquisition
In-process research and development included in liabilities
Contingent consideration liabilities related to acquisitions
Lease liability settled through transfer of lease
Modification of lease agreement
Right-of-use asset obtained in exchange for operating lease liabilities
Right-of-use asset obtained in exchange for finance lease obligation
Excise tax payable on net common stock repurchases

Reconciliation to amounts within the consolidated balance sheets
Cash and cash equivalents
Cash and cash equivalents included in assets held for sale
Restricted cash included in other long-term assets

Comments